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Background: Nodal status is paramount to tailor the need of adjuvant treatments in patients affected by apparent early-stage epithelial ovarian cancer (eEOC). Here, we aimed to estimate the prevalence of nodal involvement according to various disease characteristics in order to assess the prognostic advantages to have nodal dissection in eEOC. Patients and Methods: Data of consecutive patients undergoing comprehensive staging for eEOC were retrospectively evaluated. Logistic regression and a nomogrambased analysis were used to assess the risk of nodal involvement. Results: Overall, 377 patients were included. All patients had nodal dissection including pelvic and para-aortic lymphadenectomy in 366 and 370 cases, respectively. Fortyfour (11.7%) patients were upstaged due to nodal involvement. Pelvic and para-aortic nodal metastases were observed in 32/366 (8.7%) and 42/370 (11.3%) patients, respectively. Nodal involvement was observed in 46/136 (33.8%), 8/24 (33.3%), 15/94 (15.9%), 4/42 (9.5%) and 1/81 (1.2%) patients with serous, undiffentiated, endometrioid, clear cell, and mucinous histology (p < 0.001). Via multivariate analysis, we observed that poor differentiated tumor, (FIGO grade 3), serous histology and bilateral tumors were independently associated with both pelvic and para-aortic nodal involvement (p < 0.05). Normograms displaying the risk of nodal involvement in the pelvic and para-aortic areas were build. FIGO grade, serous histology and bilateral tumors are the main characteristics suggesting node positivity. Moreover, we observed that pelvic node involvement was more frequently detected in patients affected by FIGO stage II eEOC. Conclusions: Our data suggested that FIGO grade 3, serous and bilateral eEOC are at high risk of having disease harboring in the lymph nodes. After receiving external validation, our data will help to identify patients deserving comprehensive retroperitoneal staging. Background: Cervical cancer is underrepresented in the gynecological clinical research. The objective of this observational study was to evaluate the activity and the safety of capecitabine in patients with platinum-resistant recurrent cervical carcinoma. Materials and methods: In this phase II study we enrolled patients with advanced/ recurrent cervical carcinoma who have failed a previous platinum-based therapy. All patients signed an informed consent and were treated at the Gynecological Units of the IRCCS National Cancer Institute of Milan (Italy). All patients received a starting dose of oral capecitabine 1250 mg/m2 twice a day continuously from day 1 to day 14 every 21 days. We used RECIST 1.1 criteria to evaluate response to therapy and CTCAE 4.0 to evaluate AE. Progression-free survival (PFS) was defined as time from first capecitabine intake to progressive disease (PD) and overall survival (OS) as time from first capecitabine to cancer-related death. We performed descriptive analysis and Kaplan Meier test using SPSS 20.0. Results: From Dec 2013 to Jan 2017, 20 patients were enrolled. All patients receive a combination of carboplatin/paclitaxel as first-line therapy for advanced/recurrent disease. Median age at the first capecitabine administration was 56.9 years (range 27-82). After a median follow-up of 14.3 months (range 3-39.6), 2 patients were on treatment, 18 patients experienced a PD with a median PFS of 4.7 months and 16 patients died (median OS 14.4 months). With a median exposure to capecitabine of 4.5 cycles (range 3-15), 5% complete responses, 30% partial responses and 25% stabilization of disease were reported. After capecitabine, 65% of patients received further chemotherapy (median 2 lines, range 0-5). No grade!3 adverse events (AE) were reported; the most frequent grade 2 AE were fatigue (55%), hand-foot syndrome (40%) and diarrhea (20%). Overall, 5 patients received a reduced dose of capecitabine (1000 mg/m2 twice a day) due to AE (1 grade 2 diarrhea, 2 grade 2 fatigue and 2 grade 2 hand foot syndrome). Conclusions: Our study suggests that oral capecitabine should be considered an active and safe treatment in patients with platinum-presistant advanced/recurrent cervical carcinoma. Background: Until the results of the ENGOT-EN2-DGCG/EORTC 55102 trial will become available, the role of adjuvant chemotherapy (CT) in patients with high-intermediate and high risk, early stage, lymph node negative (LN0), type 1 endometrial cancer is unclear. Methods: We retrospectively collected patients diagnosed with endometrioid endometrial cancer stage 1a and b (2009 FIGO staging), LN0, and grade 3. We performed descriptive analysis and Kaplan Meier test using SPSS 20.0. Results: From March 1996 to Oct 2016, 54 consecutive patients were identified and enrolled (46 at the National Cancer Institute of Milan and 8 at the University Hospital of Udine). Median age at diagnosis was 65.4 years (range 34.2-84.9). All patients were documented to be LN negative, 27 patients underwent pelvic lymphadenectomy (PLD), 19 PLD plus lomboaortic (LA), and 8 sentinel lymph nodes biopsy. Overall, 35 patients had lymphovascular space involvement (LVSþ) and 11 had not, in 8 pathologic report this data was not reported. After surgery, 33 patients received adjuvant radiotherapy (RT): 21 patients (63.6%) received brachyRT, 8 patients (24.2%) received external RT, 4 patients (12.2%) received both; 13 patients underwent platinum-based adjuvant chemotherapy (CT): 7 only CT, 2 external RT followed by CT and 2 brachyRT followed by CT. To note, among patients who received CT, 84.4% had LVSþ. After a median follow up of 51.1 months (range 6-249), 14 patients (25.9%) experienced disease relapse and 12 patients (22.2%) died (9 due to endometrial cancer, 2 breast cancer and 1 pancreatic cancer). Median disease-free survival (DFS) was 19.9 months (range 4.7-157.4). Only 1 patients who underwent CT experienced disease relapse, the relapse rate was 7.7% in CT group versus 31.7% in non-CT group (P ¼ 0.085). Conclusions: According to our study, patients with stage 1a and b, LN0, grade 3 endometrioid endometrial cancer seems to derive a great benefit from adjuvant chemotherapy. This data needs to be further investigated in a large prospective clinical trial. Background: The immune system plays an important role against tumor growth. Accumulating evidence indicates that chemotherapy might influence the activity of resident and recruited immune cells that contrast tumor proliferation. Here, we aimed to investigate the impact of hematologic toxicity and leukopenia in locally advanced cervical cancer patients undergoing neoadjuvant chemotherapy (NACT). Patients and methods: Data of consecutive patients undergoing platinum-based NACT followed by surgery were collected in order to evaluate the impact of chemotherapy-related toxicity on survival outcomes. Toxicity was graded per the Common Terminology Criteria for Adverse Events (CTCAEv.4.03). Survival outcomes were evaluated using Kaplan-Meir and Cox hazard models. Results: Overall, 126 patients were included. Among those, 94 (74.6%) patients experienced grade2þ hematologic toxicity; while, grade2þ non-hematologic toxicity occurred in 11 (8.7%) patients. After a median follow-up of 37.1 (inter-quartile range, 12-57.5) months, 21 (16.6%) patients experienced recurrence. Via multivariate analysis, no factor was independently associated with disease-free survival; while a trend toward worse prognosis was observed for patients experiencing grade2þ leukopenia at cycle-3 (HR:3.13 (95%CI: 0.94, 10.3); p ¼ 0.06). Similarly, grade2þ leukopenia (HR:9.98 (95%CI: 1.14, 86.6); p ¼ 0.03), lymph-node positivity (HR:14.6 (95%CI:1.0, 214.4); p ¼ 0.05) and vaginal involvement (HR:5.81 (95%CI:1.43, 23.6); p ¼ 0.01) impacted on overall survival, at multivariate analysis. Magnitude of leukopenia correlated with survival (p < 0.001).
H3 Is chemotherapy worthwhile in patients with
Conclusions: The present study shows an association between the occurrence of leukopenia and survival outcomes. NACT-related immunosuppression might reduce the response against the tumor, thus promoting cancer progression.
